Compare Stocks: GALT, SLDB, LXRX, and CADL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$13.28 -2.4%	$10.40	$4.35 ▼ $13.95	$1.04B	-0.51	1.29 million shs	977,973 shs
GALT Galectin Therapeutics	$4.15 +4.0%	$3.80	$2.03 ▼ $7.13	$262.77M	0.41	360,737 shs	291,096 shs
LXRX Lexicon Pharmaceuticals	$2.31 -1.3%	$2.31	$1.03 ▼ $2.68	$1.04B	1.08	2.88 million shs	1.20 million shs
SLDB Solid Biosciences	$9.72 -1.7%	$9.15	$3.79 ▼ $11.45	$1.06B	2.41	905,228 shs	594,134 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-2.35%	-1.63%	+33.33%	+64.15%	+122.82%
GALT Galectin Therapeutics	+4.01%	+13.08%	+22.78%	+61.48%	-0.24%
LXRX Lexicon Pharmaceuticals	-1.28%	-4.15%	+3.59%	+4.52%	+102.63%
SLDB Solid Biosciences	-1.72%	-0.21%	+23.19%	+37.48%	+70.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$13.28 -2.4%	$10.40	$4.35 ▼ $13.95	$1.04B	-0.51	1.29 million shs	977,973 shs
GALT Galectin Therapeutics	$4.15 +4.0%	$3.80	$2.03 ▼ $7.13	$262.77M	0.41	360,737 shs	291,096 shs
LXRX Lexicon Pharmaceuticals	$2.31 -1.3%	$2.31	$1.03 ▼ $2.68	$1.04B	1.08	2.88 million shs	1.20 million shs
SLDB Solid Biosciences	$9.72 -1.7%	$9.15	$3.79 ▼ $11.45	$1.06B	2.41	905,228 shs	594,134 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	-2.35%	-1.63%	+33.33%	+64.15%	+122.82%
GALT Galectin Therapeutics	+4.01%	+13.08%	+22.78%	+61.48%	-0.24%
LXRX Lexicon Pharmaceuticals	-1.28%	-4.15%	+3.59%	+4.52%	+102.63%
SLDB Solid Biosciences	-1.72%	-0.21%	+23.19%	+37.48%	+70.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	2.64	Moderate Buy	$19.29	45.22% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	165.06% Upside
LXRX Lexicon Pharmaceuticals	2.25	Hold	$4.55	96.97% Upside
SLDB Solid Biosciences	2.82	Moderate Buy	$17.40	79.01% Upside

Current Analyst Ratings Breakdown

Latest GALT, SLDB, LXRX, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	SLDB Solid Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$16.00 ➝ $20.00
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
8/11/2026	GALT Galectin Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/3/2026	LXRX Lexicon Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
7/23/2026	LXRX Lexicon Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	CADL Candel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SLDB Solid Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	CADL Candel Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$22.00

(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$1.65 per share	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($2.11) per share	N/A
LXRX Lexicon Pharmaceuticals	$49.80M	20.64	N/A	N/A	$0.39 per share	5.92
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
GALT Galectin Therapeutics	-$30.84M	-$0.43	N/A	N/A	N/A	N/A	N/A	-176.83%	11/13/2026 (Estimated)
LXRX Lexicon Pharmaceuticals	-$50.34M	-$0.15	N/A	N/A	N/A	-147.38%	-37.53%	-24.96%	11/5/2026 (Estimated)
SLDB Solid Biosciences	-$174.32M	-$1.91	N/A	N/A	N/A	N/A	-71.35%	-60.58%	11/2/2026 (Estimated)

Latest GALT, SLDB, LXRX, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GALT Galectin Therapeutics	-$0.09	-$0.14	-$0.05	-$0.14	N/A	N/A
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/6/2026	Q2 2026	LXRX Lexicon Pharmaceuticals	-$0.0502	-$0.06	-$0.0098	-$0.07	$3.99 million	$0.69 million
8/6/2026	Q2 2026	SLDB Solid Biosciences	-$0.4624	-$0.38	+$0.0824	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.38	16.09	16.09
GALT Galectin Therapeutics	N/A	0.10	0.10
LXRX Lexicon Pharmaceuticals	0.29	13.37	13.29
SLDB Solid Biosciences	N/A	13.82	13.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
GALT Galectin Therapeutics	11.68%
LXRX Lexicon Pharmaceuticals	74.70%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	14.30%
GALT Galectin Therapeutics	52.60%
LXRX Lexicon Pharmaceuticals	14.00%
SLDB Solid Biosciences	2.66%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	76.52 million	65.58 million	Optionable
GALT Galectin Therapeutics	9	65.86 million	31.22 million	Optionable
LXRX Lexicon Pharmaceuticals	140	444.96 million	382.66 million	Optionable
SLDB Solid Biosciences	100	107.23 million	104.37 million	Optionable

GALT, SLDB, LXRX, and CADL Headlines

Recent News About These Companies

Solid Biosciences (NASDAQ:SLDB) Trading 5.5% Higher - Should You Buy?

August 25 at 12:19 PM | marketbeat.com

Truist Financial Increases Solid Biosciences (NASDAQ:SLDB) Price Target to $20.00

August 23, 2026 | americanbankingnews.com

Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial

August 21, 2026 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 6.7% - Time to Sell?

August 20, 2026 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 20, 2026 | marketbeat.com

HC Wainwright Has Positive Estimate for SLDB Q3 Earnings

August 12, 2026 | marketbeat.com

Dimensional Fund Advisors LP Acquires 277,051 Shares of Solid Biosciences Inc. $SLDB

August 11, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Solid Biosciences (SLDB)

August 8, 2026 | theglobeandmail.com

Solid Biosciences (NASDAQ:SLDB) Posts Earnings Results, Beats Estimates By $0.08 EPS

August 7, 2026 | marketbeat.com

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | finance.yahoo.com

Solid Biosciences (SLDB) Expected to Release Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Janus Henderson Group PLC Acquires Shares of 4,010,695 Solid Biosciences Inc. $SLDB

August 3, 2026 | marketbeat.com

Stempoint Capital LP Purchases New Position in Solid Biosciences Inc. $SLDB

July 30, 2026 | marketbeat.com

Solid Biosciences Inc. $SLDB Holdings Boosted by Redmile Group LLC

July 29, 2026 | marketbeat.com

Solid Biosciences Inc. $SLDB Shares Purchased by Ally Bridge Group NY LLC

July 29, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Nuvalent (NUVL) and Solid Biosciences (SLDB)

July 7, 2026 | theglobeandmail.com

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

July 2, 2026 | seekingalpha.com

Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?

July 1, 2026 | finance.yahoo.com

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 1, 2026 | globenewswire.com

Solid Biosciences to Participate at Upcoming Investor Conferences

June 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SLDB, LXRX, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

$13.28 -0.32 (-2.35%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$13.55 +0.27 (+2.03%)

As of 04:27 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Galectin Therapeutics NASDAQ:GALT

$4.15 +0.16 (+4.01%)

As of 08/26/2026 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.31 -0.03 (-1.28%)

As of 08/26/2026 04:00 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Solid Biosciences NASDAQ:SLDB

$9.72 -0.17 (-1.72%)

Closing price 08/26/2026 04:00 PM Eastern

Extended Trading

$9.72 +0.00 (+0.05%)

As of 04:01 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, SLDB, LXRX, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, SLDB, LXRX, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, SLDB, LXRX, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SLDB, LXRX, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

Galectin Therapeutics NASDAQ:GALT

Lexicon Pharmaceuticals NASDAQ:LXRX

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GALT, SLDB, LXRX, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GALT, SLDB, LXRX, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GALT, SLDB, LXRX, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT, SLDB, LXRX, and CADL Company Descriptions

Candel Therapeutics NASDAQ:CADL

Galectin Therapeutics NASDAQ:GALT

Lexicon Pharmaceuticals NASDAQ:LXRX

Solid Biosciences NASDAQ:SLDB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools